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ABSTRACT 
After 30 years of research, the exact mechanisms underlying human immunodeficiency 
virus type 1 (HIV-1) pathogenesis and disease progression remain elusive. In the 
absence of highly active antiretroviral therapy, most HIV-infected individuals progress 
to AIDS within 10 years. The clinical course of HIV-1 infection is characterized by 
considerable variability in the rate of disease progression among patients with different 
genetic background. It has been shown that the rate of progression can depend on the 
expression of certain human leukocyte antigen (HLA) class I alleles that present 
antigen to the host immune system. The HLA-B*5701 allele is most strongly 
associated with slower progression. Underlying mechanisms are not fully understood 
but likely involve both immunological and virological dynamics. In this thesis, viral 
evolution and immunological patterns were studied in the context of HIV-1 risk of 
disease progression in HLA-B*5701 subjects and non-HLA-B*57 control subjects. 
First, HIV-1 in vivo evolution and epitope-specific CD8+ T cell responses were 
investigated in six untreated HLA-B*5701 patients monitored from early infection up 
to seven years post-infection. The subjects were classified as high-risk progressors 
(HRPs) or low-risk progressors (LRPs) based on viral load and baseline CD4+ T cell 
counts. Interestingly, polyfunctional CD8+ T cell responses were more robust in LRPs, 
who also showed significantly higher interleukin-2 production in early infection 
compared to HRPs. Additionally, HIV-1 gag p24 sequences exhibited more constrained 
mutational patterns with significantly lower diversity and intra-host evolutionary rates 
in LRPs than HRPs. Further in-depth analyses revealed that the difference in 
evolutionary rates was mainly due to significantly lower HIV-1 synonymous 
substitution [replication] rates in LRPs than HRPs. The viral quasispecies infecting 
LRPs was also characterized by a slower increase in synonymous divergence over time. 
This pattern did not correlate to differences in viral fitness, as measured by in vitro 
replication capacity, but a significant inverse correlation between baseline CD4+ T cell 
counts and mean HIV-1 synonymous rate was found. The results indicate that HLA-
linked immune responses in HLA-B*5701 subjects who maintain high CD4+ T cell 
counts in early infection are more likely to control HIV-1 replication for an extended 
time. 
To further assess these findings and evaluate them in the context of viral population 
dynamics, a new method was implemented to investigate the temporal structure of 
phylogenetic trees inferred from HIV-1 intra-host longitudinal samples. The analysis 
revealed that changes in viral effective population size (Ne) over time were more 
constrained in HLA-B*5701 subjects compared to non-HLA-B*57 controls, possibly 
due to the different evolutionary dynamics of archival viral strains observed in the two 
groups of patients. 
Explaining the differences in risk of HIV-1 disease progression among HLA-
B*5701 subjects, as well as between HLA-B*5701 and non-HLA-B*57 subjects, could 
have significant translational impact by providing specific correlates of protection that 
are essential for the successful development of a vaccine. Ultimately, the present work 
demonstrates that a thorough understanding of HIV-1 pathogenesis and disease 
progression requires a multidisciplinary approach unifying viral evolution and 
immunological patterns. 
  
  
LIST OF PUBLICATIONS 
This thesis is based on the following papers, which will be referred to in the text by 
their Roman numerals (I-IV): 
 
I Norström MM, Buggert M, Tauriainen J, Hartogensis W, Prosperi MC, Wallet 
MA, Hecht FM, Salemi M, Karlsson AC. Combination of Immune and Viral 
Factors Distinguishes Low-Risk versus High-Risk HIV-1 Disease Progression 
in HLA-B*5701 Subjects. J Virol. 2012; 86(18):9802-16. 
 
II Norström MM, Veras NM, Huang W, Prosperi MCF, Cook J, Hartogensis W, 
Hecht FM, Karlsson AC, Salemi M. Baseline CD4 Counts Determines HIV-1 
Synonymous Rates in HLA-B*5701 Subjects with Different Risk of Disease 
Progression. Submitted manuscript. 
 
III Norström MM*, Prosperi MC*, Gray RR, Karlsson AC, Salemi M. 
PhyloTempo: A Set of R Scripts for Assessing and Visualizing Temporal 
Clustering in Genealogies Inferred from Serially Sampled Viral Sequences. 
Evol Bioinform. 2012; 8:261-9. *These authors equally contributed to the work. 
 
IV Norström MM, Veras NM, Nolan DJ, Prosperi MCF, Hartogensis W, Hecht 
FM, Salemi M, Karlsson AC. Different HIV-1 Intra-Host Phylodynamic 
Patterns between HLA-B*5701 Study and Control Subjects. Manuscript. 
  
PUBLICATIONS NOT INCLUDED IN THIS THESIS 
Buggert M, Norström MM, Czarnecki C, Tupin E, Luo M, Gyllensten K, Sönnerborg 
A, Lundegaard C, Lund O, Nielsen M, Karlsson AC. Characterization of HIV-specific 
CD4+ T Cell Responses Against Peptides Selected with Broad Population and Pathogen 
Coverage. PLoS One. 2012; 7(7):e39874. 
 
Norström MM, Karlsson AC, Salemi M. Towards a New Paradigm Linking Virus 
Molecular Evolution and Pathogenesis: Experimental Design and Phylodynamic 
Inference. New Microbiol. 2012; 35(2):101-11. 
 
Lindkvist A*, Edén A*, Norström MM, Gonzalez VD, Nilsson S, Svennerholm B, 
Karlsson AC, Sandberg JK, Sönnerborg A, Gisslén M. Reduction of the HIV-1 
Reservoir in Resting CD4+ T-lymphocytes by High Dosage Intravenous 
Immunoglobulin Treatment: a Proof-of-Concept Study. AIDS Res Ther. 2009; 6:15. 
*These authors equally contributed to the work. 
 
Pérez CL, Larsen MV, Gustafsson R, Norström MM, Atlas A, Nixon DF, Nielsen M, 
Lund O, Karlsson AC. Broadly Immunogenic HLA Class I Supertype-Restricted Elite 
CTL Epitopes Recognized in a Diverse Population Infected with Different HIV-1 
Subtypes. J Immunol. 2008; 180(7):5092-100. 
TABLE OF CONTENTS 
1! Introduction ................................................................................................................. 1!
1.1! HIV virology .................................................................................................... 1!
1.1.1! ! The Origin and Spread of HIV ..................................................... 1!
1.1.2! ! Structure and Genome .................................................................. 2!
1.1.3! ! Replication Cycle .......................................................................... 3!
1.2! HIV Immunology and Pathogenesis ............................................................... 5!
1.2.1! ! The Immune System in HIV Infection ......................................... 5!
1.2.2! ! Antigen Processing and Presentation ........................................... 5!
1.2.3! ! HIV-1-Specific T Cell Responses ................................................ 6!
1.2.4! ! Transmission ................................................................................. 6!
1.2.5! ! Course of HIV-1 Infection and Disease Progression ................... 7!
1.3! HIV Molecular Evolution ................................................................................ 9!
1.3.1! ! Genetic Variation .......................................................................... 9!
1.3.2! ! Selection Pressure ....................................................................... 10!
1.3.3! ! Phylodynamics of HIV-1 Intra-Host Evolution ......................... 11!
Aims of Thesis ................................................................................................................. 13!
2! Materials and Methods .............................................................................................. 14!
2.1! Study Design and Patient Material ................................................................ 14!
2.2! Methodologies ............................................................................................... 15!
2.2.1! ! Single Genome Sequencing ........................................................ 16!
2.2.2! ! Flow Cytometry .......................................................................... 16!
2.2.3! ! Gag-Pro Mediated Replication Capacity Assay ......................... 16!
2.2.4! ! Phylogenetic Signal and Recombination .................................... 17!
2.2.5! ! Phylogeny Inference ................................................................... 17!
2.2.6! ! Selection Analysis ....................................................................... 18!
2.2.7! ! Molecular Clock Analysis .......................................................... 19!
2.2.8! ! HIV-1 Intra-host Demographic History ..................................... 19!
2.2.9! ! Temporal Clustering ................................................................... 20!
2.2.10! !Statistical Analysis ...................................................................... 20!
2.2.11! !Ethical Considerations ................................................................ 21!
3! Results and Discussion .............................................................................................. 22!
3.1! HIV-1 Immune and Viral Factors in HLA-B*5701 Low-Risk and High-Risk 
Progressors ..................................................................................................... 22!
3.2! Developing Tools to Analyze Temporal Structure of Viral Genealogies .... 26!
3.3! HIV-1 Intra-Host Phylodynamic Patterns and In-Depth Temporal Structure 
Analysis of Viral Genealogies in HLA-B*5701 Subjects and Non-HLA-
B*57 Controls ................................................................................................ 26!
4! Conclusions and Future Perspective ......................................................................... 29!
5! Acknowledgements ................................................................................................... 31!
6! References ................................................................................................................. 31!
 
  
LIST OF ABBREVIATIONS 
AIDS 
APOBEC 
APC 
CCR5 
CD4 
CTL 
CXCR4 
DNA 
Env 
ER 
Gag 
Gp  
HIV-1 
HIV-2 
HLA 
IFN 
IL 
IN 
LTR 
MHC 
mRNA 
Nef 
NKT 
PBMC 
PCR 
Pol 
PR 
Rev 
RNA 
RT 
SIV 
TAP 
Acquired immunodeficiency syndrome 
Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
Antigen presenting cell 
C-C chemokine receptor type 5 
Cluster of differentiation 4 
Cytotoxic T lymphocyte 
C-X-C motif receptor 4 
Deoxyribonucleic acid 
Envelope 
Endoplasmic reticulum 
Group-specific antigen 
Glycoprotein 
Human immunodeficiency virus type 1 
Human immunodeficiency virus type 2 
Human leukocyte antigen 
Interferon 
Interleukin 
Integrase 
Long terminal repeat 
Major histocompatibility complex 
Messenger RNA 
Negative factor 
Natural killer T cells 
Peripheral blood mononuclear cell 
Polymerase chain reaction 
Polymerase 
Protease 
Regulator of virion expression 
Ribonucleic acid 
Reverse transcriptase 
Simian immunodeficiency virus 
Transporter associated with antigen processing 
TCR 
Vif 
Vpr 
Vpu 
T cell receptor 
Viral infectivity factor 
Viral protein R 
Viral protein U 
 
  
  
  1 
1 INTRODUCTION 
 
1.1 HIV VIROLOGY 
 
1.1.1 The origin and spread of HIV 
The origin of the human immunodeficiency virus (HIV) has been traced to simian 
immunodeficiency viruses (SIVs), which have been found in African apes and 
monkeys [1-3]. It is known that SIV naturally infect approximately 40 different species 
of Old World monkeys in sub-Saharan Africa [4]. Some of these SIVs have, through 
zoonotic transmission events, resulted in different HIV types and groups. 
Transmissions from West Central African chimpanzees (Pan troglodytes troglodytes) 
established HIV type 1 (HIV-1), while transmissions from sooty mangabeys 
(Cercocebus atys atys) established HIV type 2 (HIV-2) [1]. By using sequence data 
with known sampling times, phylogenetic analysis have shown that the time to the most 
recent common ancestor for HIV-1 dates back to 1910 for HIV-1 and to 1940 for HIV-
2 [5-7]. Current estimates suggest that SIV has been present in African primates for 
more than 32,000 years [8] during which several zoonotic transmissions to humans may 
have occurred. However, it was a single (or limited) transmission about 100 years ago 
that eventually gave rise to the current AIDS pandemic, largely due to the worldwide 
spread of HIV-1 group M subtypes. The evolutionary and ecological forces driving the 
global dissemination of HIV-1 during the last three decades remain unclear, but may be 
related to social, historical and behavioural changes including decolonization, 
migration [9] and urbanization [7, 10], as well as rapid increase in infrastructure and 
human mobility [11]. 
 
Even though HIV-1 was introduced into the human population through several cross-
species transmissions, it was only about 30 years ago that recognition and identification 
of the virus began. In 1981, opportunistic diseases such as Pneumocystis carinii 
pneumonia and Kaposi’s sarcoma, combined with immune suppression was reported in 
young and previously healthy homosexual men in New York City and California [12, 
13]. Additional opportunistic complications such as mycobacterial infections, 
toxoplasmosis, invasive fungal infections and non-Hodgkin’s lymphoma were soon 
described. The disease was given the name acquired immunodeficiency syndrome 
(AIDS) [14]. However, the cause of the disease remained unknown until end of 1982 
when a child who received blood transfusions died of AIDS-related infections, 
providing the first clear evidence that AIDS was caused by an infectious agent [15]. In 
1983, the virus was isolated [16] that later was given the name HIV. Dr. Luc 
Montagnier and Dr. Francoise Barre-Sinoussi who isolated HIV were awarded the 
Noble Prize for their finding in 2008. 
 
Today, almost 30 years after the discovery of the virus, there is still no cure or vaccine. 
HIV is one of the fastest evolving organisms known [17] and its ability to rapidly 
diversify allows the virus to evade the host immune system [18]. More than 60 million 
people have been infected with HIV-1 since 1981 and more than 20 million have died 
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from AIDS-related illnesses. Today, according to UNAIDS, the virus has spread to all 
continents and about 34.2 million people are infected, with the most affected part of the 
world being sub-Saharan Africa [19, 20]. 
 
 
1.1.2 Structure and Genome 
HIV is a Lentivirus belonging to the Retroviridae family. Retroviruses are enveloped 
viruses containing two identical positive-sense single-stranded (ss) RNA molecules 
(9.2 kBp) that are non-covalently linked at the 5’-end. The virus is icosahedral with a 
diameter of approximately 100 nm and the bi-layered lipid envelope, derived from the 
host cell, contains viral trimeric glycoprotein gp41 covalently linked to the external 
trimeric gp120 (Figure 1). Inside the envelope, a protective cone-shaped nucleocapsid 
surrounds the genome and the viral enzymes reverse transcriptase (RT), protease (PR) 
and integrase (IN). The enzymes are required for specific replication events. 
 
The viral genome is approximately 10,000 nucleotides and has three major structural 
genes: envelope (env), group-specific antigen (gag) and polymerase (pol). The env gene 
encodes the viral polyprotein gp160/gp140 that is cleaved into the transmembrane gp41 
and the external gp120 (Figure 1). The gag gene encodes the polymerase precursor p55, 
which is processed by the viral protease into p24 (capsid), p17 (matrix), p7 
(nucleocapsid) and p6. The pol gene encodes the viral enzymes RT, PR and IN. The 
gag and pol genes are produced as Gag or Gag-Pol precursor polyproteins that are 
cleaved by the viral PR into functional proteins. HIV-1 also has several regulatory (tat 
and rev) and accessory (vif, vpr, vpu and nef) genes, which are important for the viral 
life cycle. 
 
 
Figure 1. HIV-1 virion and genomic organization. Adapted from MWCHO. 
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1.1.3 Replication Cycle 
The viral life cycle begins when the gp120 protein on the surface of the virus particle 
binds to the primary receptor, the CD4 molecule, on the target cell (Figure 2). CD4 
molecules are found on CD4+ T lymphocytes, macrophages, dendritic cells (DCs) and 
brain microglia [21, 22]. The virus also requires binding to the co-receptor CCR5 or 
CXR4 on the host cell for entry. After binding to the CD4 molecule, external gp120 
undergoes a conformational change allowing transmembrane gp41 to insert its 
hydrophobic terminus into the host cell membrane bringing the virion closer to the host 
cell membrane. This enables fusion of the viral and cellular membranes resulting in the 
release of the viral nucleocapsid into the cytoplasm. 
 
Once inside the cell, the capsid uncoats and genomic RNA strands, enzymes and 
additional molecules required for the initiation of transcription are released. The RT 
enzyme reverse transcribes the ssRNA genome into a complementary strand of DNA 
[23]. The template RNA is degraded by the ribonuclease H (RNase H) domain of the 
HIV polymerase and a complementary DNA strand is synthesized, creating a double 
stranded (ds) DNA of the genome. During the reverse transcription, long terminal 
repeats (LRTs) are added to both the 5’- and 3’-end of the DNA and are crucial for 
facilitating the subsequent transcription of the viral genome. Afterwards, IN form a pre-
integration complex with the dsDNA and other viral and cellular proteins and enters the 
nucleus where the HIV-1 genome is inserted into the host genome [23]. After 
integration, the viral DNA is referred to as a provirus and remains permanently 
associated with the host genome [24]. 
 
The integrated proviral DNA is transcribed by host RNA polymerase II to produce 
novel viral genomes or viral messenger RNA (mRNA). The regulatory proteins are the 
first to be translated during this process. These regulatory proteins, amongst other 
things, facilitate the expression of the late structural viral proteins. The transactivator 
for transcription (Tat) protein forms complexes with several cellular proteins and 
enhance transcription of viral RNA by binding the trans-activating response region in 
the LTRs of the viral genome [25, 26]. The regulator of viral expression (Rev) protein 
increases the expression of the viral Gag, Env and Pol poly-proteins as it binds Rev-
responsible elements. These are present in the viral RNA facilitating the export of 
unspliced viral mRNA from the nucleus [25, 26]. The negative regulatory factor (Nef) 
protein accelerates the endocytosis and subsequent degradation of CD4 and major 
histocompatibility complex (MHC) class I molecules allowing the cell to evade 
recognition by the immune system [25, 26]. 
 
Besides the regulatory proteins, three accessory proteins – viral infectivity factor (Vif), 
viral protein R (Vpr) and viral protein U (Vpu) – are expressed from the viral genome. 
Vif counteracts the antiretroviral effect of apolipoprotein B mRNA editing enzyme 
catalytic polypeptide-like 3G (APOBEC3G), which is a protein that inhibits retroviral 
infection by hypermutating the negative RNA strand during reverse transcription 
resulting in deamination of the proviral DNA [27, 28]. The Vpr constitutes a part of the 
pre-integration complex and the Vpu enhances the release of virions from the surface of 
the cell [27, 28]. 
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Figure 2. HIV replication cycle: 1) fusion of HIV to the host cell surface, 2) viral RNA, RT, 
IN and other viral proteins enter the CD4+ T cell, 3) viral DNA is formed by reverse 
transcription, 4) viral DNA is transported across the nucleus and integrated into the host 
DNA, 5) new viral RNA is used as genomic RNA and to make viral proteins, 6) new viral 
RNA and proteins move to surface of the cell and a new virus forms, and 7) the virus matures 
by protease releasing individual HIV proteins. Adapted from NIAID. 
 
The Env gp160 precursor protein is expressed and glycosylated in the endoplasmatic 
reticulum (ER) and subsequently cleaved by the cellular protease furin into gp120 and 
gp41 in the Golgi apparatus. They are transported to the cell surface, where trimers of 
transmembrane gp41 protein associate to trimers of the extracellular gp120 protein. 
Concurrently, two copies of the viral genome and Gag (p55) and Gag-Pol (p160) poly-
proteins are assembled at the cell membrane. After budding of the immature virions, 
the viral Protease (PR), which is auto-cleaved from the Pol precursor protein, cleaves 
the Gag and Gag-Pol poly-proteins into: p17 (matrix protein), p24 (capsid protein), p7, 
p6 (nucleocapsid protein) and the viral RT, IN and PR enzymes [23]. This last step of 
the replication completes the HIV life cycle and the mature virion can infect other cells. 
CD4+ T Cell 
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1.2 HIV IMMUNOLOGY AND PATHOGENESIS 
 
1.2.1 The Immune System in HIV Infection 
The innate immune system is the first line of defence against HIV-1 acting within a few 
hours after infection. It is often referred to a non-specific response as it recognizes 
conserved patterns on pathogens and damaged cells. This is followed by the adaptive 
immune response which needs weeks to fully mature as it is tailored towards the 
infecting pathogen. There are two arms of the adaptive immune system: the humoral 
and cellular response. The humoral immune response is built up by antibody-producing 
B cells, while the cellular immune response is composed of a variety of T cell 
populations. Both B and T cells originate from the same haematopoietic stem cells in 
the bone marrow, but B cells develop in the bone marrow while T cells mature in the 
thymus. Both of these cell types express antigen-specific receptors that, upon encounter 
with antigen, induce rapid cellular proliferation. This clonal expansion of antigen-
specific effector cells is essential to enable control of the HIV-1 infection. T cells can 
be divided further into several subsets including CD4+ T cells, CD8+ T cells and NKT 
cells. The focus will, hereafter, be on the adaptive immune system and specifically 
CD8+ T cells. 
 
 
1.2.2 Antigen Processing and Presentation 
After a CD4+ T cell becomes infected with HIV-1, viral antigens are processed and 
presented by MHC class I on the surface of the infected cell. MHC class I molecules 
consist of two polypeptide chains: " and #2-microglobulin (b2-m). The heavy " chain 
consists of the three domains "1, "2 and "3. The two chains are linked non-covalently 
via interaction of b2-m and the "3 domain. The heavy " chain is highly polymorphic 
and encoded by a HLA gene, while the light b2-m subunit is not polymorphic and 
encoded by the b2-m gene. 
 
During antigen processing, viral proteins are degraded in the cytoplasm by the 
proteasome into 8-11 amino acid long epitopes. These antigenic peptides are 
transported from the cytoplasm into the endoplasmic reticulum (ER) via the transporter 
associated with antigen processing (TAP) proteins, where they are loaded into the 
MHC class I molecule. The MHC class I-peptide complex is then transported to the cell 
surface via the Golgi complex and presented to CD8+ T cells. The "3 domain is plasma 
membrane spanning and interacts with the CD8 co-receptor of T cells, while the "1 and 
"2 domains fold to make up the peptide (antigen) binding groove. 
 
The HLA class I alleles are the most polymorphic genes in the human genome and can 
be further divided into A, B and C alleles. The number of different alleles in each 
individual depends on whether the person is homozygotic or heterozygotic at each 
locus. Importantly, different HLA alleles have different binding specificities. 
Individuals with a heterozygote HLA composition may have an advantage in fighting 
most infections since a broader variety of antigens can be presented compared to 
homozygotes. The same epitope can be presented by different HLA alleles [29, 30], but 
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the impact on the pathogen may differ depending on the specific allele presenting the 
antigen [31]. 
 
 
 
 
Figure 3. Illustration of antigen presentation in CD4+ T cells, where the viral peptide:MHC 
class I complex is presented on the surface of the HIV-1-infected CD4+ T cell. CD8+ T cells 
that bind to the HLA-peptide complex with their T cell receptor can recognize the antigen and 
become activated. Courtesy of Annika C Karlsson. 
 
 
1.2.3 HIV-1-Specific T Cell Responses 
CD8+ T cells express the CD8 glycoprotein at their surface and recognize their targets 
by binding to antigen associated with MHC class I. CD8+ T cells are important in the 
control of the virus during infection [32]. Upon activation, CD8+ T cells (also known as 
cytotoxic T cells or CTLs) can kill infected cells through the release of cytotoxic 
granules containing perforin and granzymes [33, 34] and produce antiviral cytokines 
(e.g. IFN-$ and IL-2) and chemokines (e.g. MIP-1#). Killing may also occur through 
the Fas-mediated pathway, where the Fas ligand (Fas-L) on the surface of CD8+ T cells 
binds to the Fas receptor, a death receptor, on the target cell inducing target cell 
apoptosis. However, the perforin-mediated killing is believed to be of greater 
importance in viral infections [35]. CD8+ T cells need three signals to become fully 
activated. First, the T cell receptor (TCR) will recognize and bind to the proper 
MHC:epitope complex. Second, co-stimulatory molecules on the T cells interact with 
molecules on the antigen-presenting cell. Thirdly, cytokines are needed in order to 
facilitate differentiation and proliferation of the antigen-specific CD8+ T cells.  
 
 
1.2.4 Transmission 
There are three major routes of human-to-human HIV-1 transmission: i) sexual, ii) 
blood or blood product and iii) mother-to-child. The most common route of HIV 
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transmission is sexual (both heterosexual and homosexual) intercourse through the 
mucosa in the genitals, rectal and oral tracts. HIV blood transmission can occur through 
blood transfusion, organ transplantation, needle exchange among intravenous drug 
users, and needle accidents in health care and laboratory settings. Finally, mother-to-
child transmission can occur during pregnancy, birth or breastfeeding. The risk of 
transmission depends on the transmission route, the presence of other infections and 
level of viral load exposure. Genital exposure constitutes a considerably lower 
transmission risk compared to rectal exposure and there is a higher risk of infection if 
the viral load during exposure is higher [36]. The viral load is dramatically lowered by 
antiretroviral treatment, which reduces risk of HIV-1 transmission [37-39]. 
 
It has been shown that HIV-1 diversity is low during primary infection [40-44] and 
most HIV-1 infections are probably established by one or a few virions [41, 45, 46]. It 
is still unclear if several virions are transmitted during HIV-1 infection. However, only 
one or a few virions grow out and transmission bottlenecks have been seen in both 
infection through intravenous drug use and mucosal transmission [47]. In the absence 
of treatment, the viral diversity increases during the course of the HIV-1 infection [48-
50], but decreases later when progressing to AIDS [51]. 
 
 
1.2.5 Course of HIV-1 Infection and Disease Progression 
The natural course of HIV-1 infection in untreated subjects includes three main stages: 
the acute infection, clinical latency and progression to AIDS (Figure 4). During the 
acute stage of infection, the viral load reaches a peak level and there is a massive 
destruction of CD4+ T cells [52, 53].  Around 80% of the CD4+ T cells are depleted in  
the gut-associated lymphoid tissue (GALT) [54, 55]. During the acute phase many 
individuals experience “flu-like” symptoms [56]. After a few weeks, when the adaptive 
immune response has matured, the peak viremia drops to a steady state level [57] 
resulting in partial recovery of the CD4+ T cells. The subsequent chronic phase (clinical 
 
 
 
Figure 4. Clinical course of HIV-1 infection showing CD4+ T cell count  
(blue) and viral load levels (red) throughout disease progression. Adapted 
from [58]. 
AIDS 
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latency), characterized by slow but constant depletion of CD4+ T cells, can last for 
years. During the chronic phase, the immune system is continuously activated due to 
on-going viral replication eventually leading to exhaustion and a general defect in 
immune responsiveness [59] and the potential onset of several opportunistic infections. 
According to current guidelines, the AIDS phase begins when the CD4+ T cell count 
drops below 200 cells/mm3. 
A small percentage (! 1 %) of HIV-infected individuals spontaneously control viral 
replication in the absence of antiretroviral therapy. While there is no universally 
accepted definition for this rare group of HIV-infected individuals, they generally are 
called elite controllers (EC), elite suppressors (ES) or elite non-progressors (ENP). 
These terms cover individuals with viremia below the detection limit of standard viral 
load assays (50 or 75 copies/mL) for one year or more [60]. Some patients are also 
referred to as HIV controllers and are able to maintain viremia at ! 400 copies/ml for 
five years or more after infection [61]. The definition of these patients is virological 
and should not be confounded with another group of patients whose condition 
progresses slowly to AIDS. They are called long-term survivors (LTS), long-term 
asymptomatics (LTA) and long-term non-progressors (LTNP) and the definition is 
based on a CD4+ T cell count greater than 500/mm3 for several years without 
antiretroviral treatment. These patients were first described in the 1990s, but 
gradually the majority experienced a decrease in CD4+ T cell counts with a significant 
fraction progressing to AIDS. In contrast, HIV controllers appear to have a 
considerably lower risk of progressing to AIDS [62]. 
There are several known host genetic factors associated with HIV-1 control. The HLA 
allele B*57, and to a lesser extent B*27, are associated with slower rate of HIV-1 
disease progression [63]. In contrast, there are HLA alleles associated with an increased 
rate of progression, such as B*35, where patients progress to AIDS within 2-3 years 
[64]. Another host factor is the delta-32 deletion on the CCR5 gene (CCR5%32). 
Studies have shown that individuals infected with HIV-1, who have specific genetic 
mutations in one of their two copies of the CCR5 gene, progress to AIDS slower than 
individuals with two normal copies. There are also rare individuals with two mutant 
copies of the CCR5 gene who (in most cases) appear to be protected from HIV 
infection [65, 66]. Gene mutations in other HIV co-receptors, such as CXCR4, may 
also influence the rate of disease progression. Additionally, it has also been shown that 
plasma viral load and CD4+ T cell counts at baseline can be prognostic markers of HIV-
1 infection [67]. 
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1.3 HIV MOLECULAR EVOLUTION 
 
1.3.1 Genetic Variation 
HIV-1 is characterized by high genetic variability as well as rapid evolution and 
diversification [68]. The rapid evolution of the viral genome is the result of several 
factors, including elevated error rate of the reverse transcriptase, recombination and 
rapid turnover of HIV-1 in infected individuals [69]. The HIV-1 evolutionary rate is 
estimated to be approximately one million times faster than the rate of cellular genes in 
higher organisms (Figure 5) [70]. Introduction of point mutations into the viral genome 
is mediated by the RT enzyme during the reverse transcription phase of the viral 
replication cycle, where the error frequency of RT has been estimated to be as high as 
3.4&10-5 substitutions per site per replication cycle [71]. Considering that the size of the 
HIV-1 genome is approximately 10,000 bases, such an error rate results in the 
introduction of one nucleotide substitution every second to third newly synthesized 
viral genome. Moreover, highly variable regions, e.g. the hypervariable domains in the 
surface glycoprotein gp120, can display significant length polymorphism due to the 
frequent occurrence of RT-mediated insertions and deletions (indels). HIV-1 genetic 
diversity is further escalated by recombination, which is the result of strand switching 
during reverse transcription in superinfected cells. It has been estimated that 
recombination events may occur two to three times per replication cycle [72] and can 
significantly impact the immune systems’ ability to control the infection, the emergence 
of drug-resistant viral variants and allow viruses to survive genomic damage [73]. 
 
Figure 5. Evolutionary rates of different organisms. Adapted from [74]. 
 
HIV-1 fast replication rate and high number of viral particles produced per unit time are 
two other important factors contributing to the rapid evolution of the virus. The time 
from the release of a virion until it infects a new cell and eventually releases a progeny 
of its own (generation time) has been estimated to be approximately 2-3 days [75, 76] 
and every day ~109 new viral particles are produced [75, 77]. As a consequence of all 
the factors mentioned above, HIV-1 positive patients are usually infected with a highly 
heterogeneous viral population consisting of a pool of genetically distinct yet related 
viruses called quasispecies [78, 79]. The genetic variability of the HIV-1 quasispecies, 
that can reach up to 10% nucleotide diversity within an infected subject, provides the 
viral population with the ability to adapt rapidly to changes in its environment, and is 
the main challenge for the development of a vaccine or a treatment able to eradicate the 
infection. 
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1.3.2 Selection Pressure 
Changes in the environment impose selective pressure on evolving populations 
resulting in the fixation of genetic variants with genes best adapted to the new milieu 
they were selected for. Adaptation at the molecular level can be studied by analyzing 
synonymous to nonsynonymous substitutions. Synonymous substitutions, also called 
silent substitutions, do not alter the encoded amino acid and occur mostly at the third 
position of a codon. Nonsynonymous substitutions, on the other hand, result in a 
change of the encoded amino acid. Synonymous substitutions are usually neutral, or 
nearly-neutral, and are fixed in by random genetic drift. According to the neutral theory 
of molecular evolution, in the absence of positive selection, the evolutionary 
(nucleotide substitution or fixation) rate is equal to the mutation rate. Therefore, the 
synonymous substitution rate of any retrovirus is expected to be equal to the RT error 
rate, which is in turn proportional to the viral replication rate [80]. On the other hand, 
the rate of nonsynonymous substitutions may depend on selective pressure that can 
increase (positive selection) or decrease (negative selection) the fixation probability of 
specific amino acid changes, in which case nonsynonymous substitution rates can be 
used as a measure of the adaptation rate. 
 
In practice, the ratio of nonsynonymous and synonymous substitutions (dN/dS) is often 
employed to investigate natural selection and random genetic drift at the molecular 
level. A ratio around one indicates that neutral (dS) and adaptive (dN) mutations occur 
at the same rate, which is only possible in the absence of selection. On the other hand, 
dN/dS<1 indicates that the synonymous substitution rate is greater than the 
nonsynonymous one, which is expected in the presence of negative (purifying) 
selection removing genetic variants with new amino acid changes. The majority of 
amino acid replacements are usually under negative selection because of protein 
structural constraints necessary to maintain the biological function. A dN/dS>1 is 
evidence of positive (diversifying) selection occurring when amino acid changes 
increase fitness. 
 
HIV-1 intra-host evolution is driven by the dynamic interplay between viral evolution 
and host immune system, which can result in the selection of viral variants with 
reduced sensitivity to CTLs and neutralizing antibodies. It has been shown that 
emergence of viral escape mutants, in case of CTLs, is associated with disease 
progression [81, 82]. CTL escape mutants can emerge shortly after acute infection and 
become the dominant viral strains in the infected individual [83]. Rapid emergence of 
CTL escape variants indicates their pre-existence in the viral population and points to 
the dominant role of CTLs as a selective force in the infection [81]. It is also important 
to mention that the emergence of CTL escape mutations is also correlated with loss of 
viral replication fitness [84]. Antiretroviral treatment also exerts strong selective 
pressure on the infecting quasispecies that can lead to the emergence and fixation of 
low-frequency viral variants carrying drug resistance mutations. 
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1.3.3 Phylodynamics of HIV-1 Intra-Host Evolution 
Phylodynamics encompass both phylogeny inference and the interaction between 
evolutionary (i.e. mutation, genetic drift, selection) and ecological (population 
dynamics and environmental stochasticity) processes, which shape the spatiotemporal 
and phylogenetic patterns of infectious disease dynamics, both at the intra- and inter-
host level [85, 86]. Phylodynamics allow the study of viral evolution by investigating 
the topology and branch lengths of genealogies to infer the viral evolutionary and 
population dynamic patterns. Several studies have shown that staircase topology is 
typical of HIV-1 intra-host evolution [51, 87], which suggests viral quasispecies 
undergo continual immune-driven selection through sequential population bottlenecks 
[88] (Figure 6). Usually, HIV-1 intra-host genealogies of longitudinally sampled 
sequences display strong temporal structure, where sequences from the same 
sampling time tend to cluster together and are the direct ancestors of sequences from 
the following time point [89].! However, the degree of temporal structure can vary 
among genealogies inferred from different data sets. Unfortunately, no previous study 
has investigated the temporal structure of HIV-1 intra-host genealogies in-depth, 
because topological differences among genealogies are difficult to quantify. The 
Temporal Clustering (TC) statistic has recently been developed to provide a 
quantitative measure of the degree of topological 'temporal clustering' in a serially 
sampled genealogy [89]. 
 
HIV-1 divergence and diversity have been shown to follow distinct patterns during the 
infection [90]. Divergence of the virus describes its evolution from a founder strain, 
while diversity is a measure of genetic variation within the virus population at a 
specific time point. When an individual becomes infected with HIV-1, a relatively 
homogenous population of the virus is harbored because transmission is usually 
associated with a significant population bottleneck [47]. The viral diversity in gag and 
env genes has been estimated to be less than 1% during transmission of HIV-1 [43, 44, 
91]. During the early period of the chronic phase, viral diversity and divergence have 
been shown to linearly increase with similar rates. The intermediate period is 
characterized by stabilization of viral diversity, while the divergence from the founder 
strain continually increases at the same pace. 
 
The chronic phase of HIV-1 evolution is characterized by a progressive increase in both 
viral divergence and diversity. It has been suggested that this phase is dominated by 
continuous pressure from the host immune system resulting in rapid turnover of the 
infecting quasispecies. The effect of intense immune-mediated positive selection on 
HIV-1 within a patient is reflected by the temporal structure of the viral genealogies 
inferred from longitudinal samples, where a main lineage usually propagates 
successfully along the trunk (backbone) of the genealogy while other lineages become 
extinct (Figure 6). In other words, the phylogenetic trees display a topological signature 
consistent with the occurrence of sequential population bottlenecks that would be the 
result of an evolutionary process driven mainly by continual immune selection rather 
than random genetic drift. 
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Figure 6. Evolution of env quasispecies in plasma. This is an example of a phylogenetic tree 
with staircase evolution and perfect temporal structure. The tree was inferred by ML using 
longitudinal plasma samples of an HIV positive pediatric patient infected by mother-to-child 
transmission. Different colors of tip labels represent sampling times of the viral strains 
according to the legend in the figure, where T1=0.3, T2=1.2 and T3=7.0 years post-infection. 
Asterisks along the backbone indicate major population bottlenecks supported by high 
bootstrap values (>85%). Courtesy of Marco Salemi. 
 
The last phase of the infection, when the immune system collapses and progression to 
AIDS begins, involves stabilization of viral divergence and decline of viral diversity. 
This observation has been explained as a consequence of CD4+ T cells depletion, which 
results in less effective selection pressure on the virus, as well as significant decrease in 
target cells capable of sustaining viral replication. In support of such a hypothesis, it 
has been shown that late infection is, in fact, characterized, by a decrease in HIV-1 
evolutionary rate [90].  
 
 I 
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AIMS OF THESIS 
 
The main objective of the present work was to unify viral evolution and immunological 
patterns to investigate risk of HIV-1 disease progression. Four specific aims were 
developed: 
 
Paper I To investigate HIV-1 in vivo evolution and functional profiles of 
epitope-specific CD8+ T cell responses in untreated HLA-B*5701 
subjects with different risk of progression. 
 
Paper II To investigate how risk of HIV-1 disease progression in HLA-B*5701 
subjects correlates to HIV-1 intra-host synonymous and 
nonsynonymous substitution rates. 
 
Paper III To implement a new method to investigate differences in HIV-1 
population dynamics through the analysis of the temporal structure of 
viral genealogies. 
 
Paper IV To characterize HIV-1 population dynamics in subjects with different 
genetic background, by investigating temporal structure and intra-host 
phylodynamic patterns in HLA-B*5701 subjects and non-HLA-B*57 
controls. 
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2 MATERIALS AND METHODS 
 
2.1 STUDY DESIGN AND PATIENT MATERIAL 
The interplay between HIV-1 evolution and the host immune repertoire determines the 
course of disease [92]. Therefore, it may be insufficient to focus separately on 
immunological or evolutionary patterns for correlates of protection. A rigorous study 
design was developed to take full advantage of the phylodynamic framework (outlined 
in Figure 7) by following specific guidelines described in Norstrom et al. (2012) [74]. 
Plasma samples were needed to obtain data for the virological studies on the HIV-1 
population in circulation at a given time point. Additionally, peripheral blood 
mononuclear cell (PBMC) samples were necessary to obtain immunological data. 
Plasma samples (stored at -80°C) and cryopreserved PBMC samples were collected 
longitudinally from subjects in the San Francisco-based HIV-1-infected cohort 
OPTIONS at the Positive Health Program, University of California [93]. The 
OPTIONS cohort contains samples from more than 600 subjects followed from 
primary HIV-1 infection. For each subject in the cohort, the time since infection was 
estimated as the midpoint between reported negative and positive tests based on data 
from serologic tests, HIV-1 RNA testing, and prior antibody testing history. In addition, 
CD4+ T cell counts (cells/mm3) and viral load (copies/mL) measurements were 
performed regularly during the course of infection for the patients included in the 
cohort. 
 
Figure 7. Flow-chart representing the major steps in phylodynamic inference linking 
experimental design and data analysis. Adapted from [74]. 
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On-going viral intra-host evolution is difficult to characterize in samples with low viral 
copy numbers and limited genetic heterogeneity [94]. All selected subjects had to have 
detectable viral load during the study period in order to increase the chance to obtain 
sufficient phylogenetic signal for a robust evolutionary analysis. There were also 
specific requirements for an in-depth phylodynamic analysis. First, longitudinal 
samples were necessary for the calibration of the molecular clock and, in general, to 
infer viral evolutionary and population dynamic patterns. Second, time intervals 
between samples had to be optimal to make sure that the quasispecies was a 
measurably evolving population (MEP), i.e. that a statistically significant number of 
mutations could be detected between sequences obtained at different time points [95]. 
If the samples were too distant, important evolutionary events may be missed. It has 
been shown that a complete viral population turnover within an HIV-1 infected patient 
requires a time interval of 6-22 months [96]. Therefore, samples from at least three 
different time points were selected for each subject, time intervals were optimized, and 
special care was taken to match the data between HLA-B*5701 subjects and non-HLA-
B*5701 controls. Unfortunately, some limitations were unavoidable due to the actual 
samples available in the OPTIONS cohort. A brief description of the patient material 
included in the different studies is given below. Full details can be found in the 
Materials and Methods of Paper I-IV. 
 
In Paper I, six HIV-1 infected individuals carrying the B*5701 allele were selected. 
All subjects were treatment naïve excluding one who received antiretroviral treatment 
for 14 months; samples from that period were excluded in the study. Longitudinal 
plasma and PBMC samples were obtained from early infection up to seven years. For 
virological analysis, plasma samples were selected from three to six time points for 
each patient. For immunological analysis, PBMC samples were selected from three 
time points during the course of the infection for each subject. 
 
In Paper II, high-resolution phylogenetic analyses were performed on sequences 
obtained from the plasma samples collected from the HLA-B*5701 subjects described 
in Paper I. Replication capacity experiments were also performed on additional plasma 
samples collected from one to four time points for each subject. 
 
In Paper III, a method was developed to investigate temporal structure and tested on 
the HLA-B*5701 data sets (Paper I and Paper II), as well as SIV data sets 
downloaded from the Genbank database. 
 
In Paper IV, six additional HIV-1 infected individual were selected as a control group. 
All subjects were treatment naïve and did not carry the B*57 allele. Longitudinal 
plasma samples were selected from early infection up to six years. 
 
 
2.2 METHODOLOGIES 
A wide range of different virological, immunological and mathematical methods was 
applied. The sections below provide a brief overview of the main methods in Paper I-
IV, as well as the advantages of using them in the different studies. More detailed 
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information about the specific methods can be found in Materials and Methods in the 
respective papers (Appendix I-IV). 
 
 
2.2.1 Single Genome Sequencing 
Plasma samples from the HLA-B*5701 subjects had, in general, low viral load and 
only 1 mL plasma was available for most time points. In order to obtain sufficient 
template recovery, substantial effort was invested to develop sensitive and robust RNA 
extraction, cDNA synthesis and PCR amplification methods [97]. Characterization of 
the genetic heterogeneity of HIV-1 intra-host quasispecies is usually achieved by 
obtaining multiple sequences through PCR/cloning or single genome sequencing (SGS) 
[98]. SGS permits individual cDNA molecules, derived from defined regions of the 
genome, to be amplified by PCR and sequenced. This significantly reduces the 
probability of re-sampling (particularly likely in samples with low viral load), as well 
as the occurrence of PCR-mediated recombination [97, 99, 100]. SGS protocols were 
developed to obtain the HIV-1 gag p24 sequences required for the studies in Paper I-
IV. Briefly, sequences were amplified from viral cDNA by limiting-dilution digital 
nested PCR. To obtain PCR products derived from single cDNA molecules, the cDNA 
was diluted until approximately 30% of the PCR reactions yielded DNA product [99]. 
The Gag p24-region was focused on since several HLA-B*5701-restricted epitopes 
(ISW9, KF11, TW10 and QW9) are located in this region of the HIV-1 genome. 
 
 
2.2.2 Flow Cytometry 
Flow cytometry is a powerful technique for the analysis of multiple parameters of 
individual cells within heterogeneous populations. It can be used to measure the 
production of several effector molecules simultaneously in T cell populations 
stimulated with autologous peptides. In Paper I, functional profiles of HIV-1-specific 
CD8+ T cell responses were identified in six HLA-B*5701 subjects using a flow 
cytometry assay. Longitudinal PBMC samples were analyzed on a standardized 8-color 
CantoII (BD Biosciences) to identify epitope-specific CD8+ T cell responses towards 
the Gag p24-region. Using flow cytometry we were able to distinguish different T 
lymphocyte populations (CD3+, CD4+ and CD8+ T cells) at a single cell level and to 
simultaneously identify production of several effector molecules (IFN-$, MIP-1#, IL-2 
and perforin). All analyses were conducted after removal of non-viable cells, stained 
with Vivid. For each HLA-B*5701 subject, PBMCs from three different time points 
were analyzed. For more detailed information see the Materials and Methods in Paper 
I. 
 
 
2.2.3 Gag-Pro Mediated Replication Capacity Assay 
A novel assay, developed by Monogram Biosciences, was used to measure the viral 
replication capacity (RC) in the HIV-1 Gag-Pro region [101]. In Paper III, plasma 
samples were selected from all HLA-B*5701 subjects. Briefly, gag and protease 
sequences were amplified by RT-PCR and transferred into a resistance test vector 
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(RTV) containing a luciferase reporter gene. Transfections of HEK293 cells with 
patient-derived gag-pro RTVs and an amphotropic murine leukemia virus envelope 
expression vector were performed to generate pseudovirus stocks for infection of 
HEK293 cells. Gag-Pro mediated RC was determined by measuring the viral infectivity 
(luciferase activity) of patient-derived pseudoviruses relative to NL3-4, the reference 
control. 
 
 
2.2.4 Phylogenetic Signal and Recombination 
HIV-1 gag p24 is usually one of the most conserved regions of the viral genome. 
Hence, the first step in the analysis was to investigate whether aligned data sets from 
the study subjects displayed sufficient phylogenetic signal to allow reliable inferences. 
In particular, it was necessary to assess that viral sequences had sufficient genetic 
variability, within and between longitudinal samples, to be considered a MEP. Several 
methods have been developed to measure the phylogenetic signal in nucleotide and 
amino acid sequence data sets. Likelihood mapping [102], transition/transversions 
versus divergence plots [103], and the Xia test for saturation [102, 104] are often 
employed to assess the reliability of an alignment for phylogeny inference [105, 106]. 
In Paper I and Paper IV, the phylogenetic signal in each data set was investigated by 
likelihood mapping method implemented in the program TREEPUZZLE [107]. 
Detailed information can be found in Materials and Methods of Paper I. 
 
It is also important to keep in mind that recombination violates the basic assumption of 
phylogeny inference (ancestry from a common ancestor). Using algorithms that do not 
explicitly model recombination (e.g. BEAST) can bias molecular clock and coalescent 
estimates [108-110]. Recombinant strains should, therefore, be excluded and analyzed 
separately or with more complex coalescent models [111, 112]. In Paper I and Paper 
IV, the presence of potential recombinant sequences was investigated with the PHI test 
based algorithm [113] and calculations were performed with the SplitsTree package 
version 4.8 [114]. It has been shown that the PHI test is the most robust method for 
detection of recombinants within intra-host sequences that are closely related and 
display lower diversity [115]. 
 
 
2.2.5 Phylogeny Inference 
HIV-1 intra-host genealogies were inferred with several tree-building algorithms. 
Neighbor-Joining (NJ) trees were constructed to exclude contamination and confirm 
that all strains were subtype B (Paper I and Paper II).  NJ is a fast, bottom-up 
clustering algorithm that can be used to quickly analyze large data sets. It is based on 
the computation of pair-wise distances, with an explicit evolutionary (nucleotide 
substitution) model, which are in turn employed to infer the phylogenetic tree [116]. 
It has been shown that NJ trees are accurate as long as the input distance matrix is 
correct and “nearly additive”, i.e. if each entry in the distance matrix differs from the 
true distance by less than half of the shortest branch length in the tree [117]. Since 
these properties are seldom satisfied in real data sets, phylogenies were also obtained 
by more sophisticated character-based methods using the maximum likelihood (ML) 
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optimality criterion [117, 118]. ML is statistically sound, makes use of all sequence 
information, but is slower than NJ and must rely on heuristic algorithms (which do 
not guarantee to find the true ML tree) for data sets including more than 8-12 
sequences. In order to assess the robustness and statistical significance of the inferred 
tree topologies, ML and NJ trees obtained from each alignment were compared for 
topological consistency. Bootstrapping (500 replicates), as well as the approximate 
likelihood ratio test (aLRT) were used to assess the reliability of specific 
monophyletic clades. In particular, the Shimodaira-Hasegawa-like aLRT compares 
the likelihoods of the best and the second best alternative arrangements around the 
branch of interest. For both NJ and ML trees, the best-fitting evolutionary model was 
chosen with the hierarchical likelihood ratio test described by Swofford and Sullivan 
[117]. ML and NJ calculations were performed with PAUP* 4b10, written by David 
L. Swofford, and MEGA 5.0 [119], respectively. In Paper I, Paper II and Paper IV, 
HIV-1 genealogies were also inferred by Bayesian inference, which generates a 
posterior distribution for a specific parameter (such as a phylogenetic tree and a 
model of evolution), based on the prior distribution for that parameter and the 
likelihood of the data (i.e. the multiple sequence alignment). Bayesian genealogies 
were inferred with the program BEAST [120, 121], which implements a Markov 
chain Monte Carlo (MCMC) algorithm [122] to sample trees from a coalescent-based 
prior. In brief, after the posterior tree distribution is obtained with the MCMC, a 
maximum clade credibility tree (also called MAP or MCC tree), i.e. the tree with the 
greatest posterior probability averaged over all branch lengths and substitution 
parameter values, is chosen from the distribution. The posterior probability of a 
specific clade in the tree can also be calculated easily from the posterior distribution. 
MAP trees were selected with the TreeAnnotator program distributed within the 
BEAST package. Bayesian inference has several advantages over classic NJ and ML 
methods. First of all, it explicitly models for uncertainty in the phylogenetic 
reconstruction, since a posterior distribution of possible trees, rather than a single tree 
(as in clustering on ML-based algorithms), is obtained. In addition, the BEAST 
software allows for the calibration of clock-like trees (see below) [123, 124] and can 
estimate absolute evolutionary rates when sequences collected longitudinally with 
known sampling times are available. Full details on the settings used in each analysis 
can be found in the Materials and Methods of the respective papers. 
 
 
2.2.6 Selection Analysis 
ML-based methods were employed to investigate selection at the molecular level. In 
particular, for each patient-specific data set, it was interesting to identify potential HIV-
1 gag p24 sites under positive selection, as well as to compare selective pressure among 
groups of patients with different risk of disease progression. In Paper I, the presence of 
sites under positive selection was investigated using different ML codon substitution 
models implemented in the codeml program of the PAML 4.2 software package [125]. 
Initial codon-based branch lengths and nonsynonymous/synonymous (dN/dS) ratio 
were estimated for each ML tree with the M0 (one ratio) model, which assumes the 
same dN/dS along each branch of the tree [126, 127]. Positive selection analysis was 
then performed using the tree with codon-based estimated branch lengths. Three sites 
models were compared [128, 129]: M7, assuming a beta distribution of substitution 
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rates across sites; M8, assuming a beta distribution and dN/dS > 1 (positive selection) 
across sites; M8a, assuming a beta distribution and dN/dS = 1 (neutrality). The M7 
(null hypothesis) and M8 model were compared with a chi-square test with 2 degrees of 
freedom (M7 rejected when LR > 5.99). The M8a (null hypothesis) and M8 model 
were compared using a 50:50 mixture of point mass 0 and a chi-square test with a 
critical value of 2.71 at the 5% level (see PAML documentation for more details). 
Specific amino acid changes along the internal branches of the tree were inferred by 
maximum likelihood reconstruction of ancestral sequences using PAML. 
 
 
2.2.7 Molecular Clock Analysis 
In Paper I, Paper II and Paper IV, for each of HIV-1 gag p24 patient-specific data set 
molecular clock analysis was performed using the MCMC approach implemented in 
BEAST version 1.7 [121]. The analyses were performed with the same nucleotide 
substitution model selected for the phylogeny inference. Viral evolutionary rates were 
estimated by enforcing either a strict or a relaxed molecular clock (assuming, across the 
phylogeny, constant evolutionary rate or branch-specific evolutionary rates drawn from 
a lognormal prior distribution, respectively) and different population size coalescent 
priors (constant, exponential and non-parametric Bayesian skyline plot with four bin 
categories) [130]. For each analysis two independent MCMC were run, which were 
combined with the LogCombiner program in the BEAST package. The effective 
sample size (ESS) value for each parameter was > 500 indicating sufficient mixing of 
the Markov chain. The molecular clock hypothesis was then tested by comparing the 
marginal likelihood of the strict and the relaxed clock model. Estimated marginal 
likelihoods were used to compute the Bayes Factor (BF) where evidence against the 
null hypothesis (strict clock) is assessed in the following way: 2 < BF < 6 indicates 
positive evidence against the null hypothesis, 6 < BF < 10 indicates strong evidence 
against the null hypothesis, BF > 10 indicates very strong evidence against the null 
hypothesis. In Paper I, marginal likelihoods were estimated by bootstrapping via 
importance sampling and in Paper IV they were estimated with the newly developed 
stepping stone model [131], which is more reliable. Additionally, in Paper I, ML 
estimates of the coefficient of variation (CoV) under the relaxed clock model were 
obtained to assess the overall degree of rate heterogeneity across the genealogies [123]. 
In Paper II and Paper IV, for each patient data set, absolute rates of synonymous and 
nonsynonymous substitutions were estimated using 200 randomly chosen trees from 
the posterior distribution obtained with BEAST and implementing the method 
described by Lemey et al. (2007) [132]. 
 
 
2.2.8 HIV-1 Intra-host Demographic History 
The demographic history of a population can be inferred from the genealogical 
relationships of sampled individuals by applying coalescent theory [133]. A genealogy 
reconstructed from randomly sampled HIV sequences, for example, contains 
information about population-level processes such as change in population size and 
growth rate [134]. In Paper IV, three different demographic models or each data set 
were investigated for the HIV-1 intra-host quasispecies by enforcing the best fitting 
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molecular clock model: constant population size, exponential population growth, and 
Bayesian skyline plot (BSP). Both parametric (constant or exponential model) and non-
parametric BSP estimates of demographic history were performed and compared by 
BFs as described in the previous section. 
 
 
2.2.9 Temporal Clustering 
Evolutionary trees estimated from serially sampled sequence data are shaped by a 
complex interaction of demographic factors and selective pressure. Those obtained 
from genes under strong and continual positive selection are reported to exhibit a 
‘ladder-like’ shape, characterized by (i) phylogenetic asymmetry and (ii) a tendency 
for sequences sampled at similar times to cluster together [88]. The temporal 
clustering (TC) statistic, based on parsimony estimates, was recently developed to 
quantify ‘ladder-likeness’ of a phylogenetic tree topology by taking into account the 
sampling time of the tips [89]. However, an improved TC statistics based on 
Maximum Likelihood (ML) estimates of ancestral characters was implemented in the 
R language by developing a set of R scripts, called PhyloTempo. Several additional 
topological measures were also integrated in a user-friendly graphical interface. The 
TC statistic assesses the temporal structure of a phylogenetic tree by assigning a 
discrete character corresponding to the sampling time (T1, T2, … Tn) to each tip and 
using ML ancestral trait mapping [135] to calculate the number of time transitions 
(from Ti to Tj with i<j) in the genealogy. If there are n different states at the tips of a 
phylogeny, the minimum number of ancestral state transitions observed across the 
phylogeny would be n-1.! A greater number of ancestral state transitions indicate a 
deviation from a perfect temporal structure. For detailed information about the 
temporal clustering statistics see Materials and Methods in Paper III. In Paper IV, 
the TC calculations for each HIV-1 genealogy were performed with the PhyloTempo 
software running under the R package [135]. Additionally, by recording the number 
of ancestral state transitions (NAST) in the genealogy for each pair of discrete 
characters (i.e., Ti and Tj with i<j), it is possible to assess whether the observed NAST 
is significantly greater (p<0.05) than the one expected in the null distribution of 1000 
trees with randomly shuffled tip characters. NAST significantly exceeding the null 
expectation indicates the emergence (or re-emergence) of archival viral strains. 
 
 
2.2.10 Statistical Analysis 
In Paper I, experimental variables between two groups of individuals were analyzed 
using unpaired t-test, Student’s t-test, Mann-Whitney U-test and Wilcoxon matched-
pairs rank test. One-way ANOVA with post hoc Dunn’s multiple comparison tests 
(non-parametric) was used to analyze three or more groups. Correlations were assessed 
using non-parametric Spearman rank tests. All pie charts were analyzed by permutation 
tests using the data analysis program SPICE version 5.2 (11). In Paper II, experimental 
variables between groups of individuals were compared using the Mann-Whitney U-
test. Mean nonsynonymous and synonymous rates for different set of branches in the 
phylogenetic trees (all, internal, backbone and external) were compared to the 
corresponding clinical parameters of each patient (baseline CD4 count, baseline VL, 
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CD4 slope, VL slope and baseline T cell activation) using Pearson’s linear correlation 
to calculate the associated t-values and assess significance. All p-values obtained from 
applying any test statistic multiple times were adjusted with the Bonferroni correction. 
In Paper I and Paper IV, slopes of CD4+ T cell counts and viral load (VL) were 
obtained from least squares regression of log-transformed CD4 counts and VL over 
time (years). Model coefficients were back transformed and converted from proportions 
to percentage effect by subtracting one and multiplying by 100 to obtain individual 
estimates of percent change over time. Full details on the statistical test used in each 
analysis can be found in the Materials and Methods of the respective papers. 
 
 
2.2.11 Ethical Considerations 
The University of California, San Francisco (UCSF), Committee on Human Research 
and the Regional Ethical Council in Stockholm, Sweden (2008/1099-31), approved the 
studies in Paper I-IV. For the studies included in Paper IV, ethical approvals were 
obtained by the Committee on Human Research at University of Florida (258-2012). 
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3 RESULTS AND DISCUSSION 
The clinical course of HIV-1 infection is characterized by considerable variability in 
the rate of disease progression among patients with different genetic background, where 
HLA-B*5701 is the allele most strongly associated with slower progression. The exact 
mechanisms underlying HIV-1 pathogenesis are not fully understood, but they likely 
involve the interplay between host immune system and viral evolution. Most of the 
previous studies have focused either on intra-host viral evolution or on functional 
aspects of the immune system, which may be insufficient for identifying correlates of 
protection. The present work focuses on HIV-1 disease progression in HLA-B*5701 
and non-HLA-B*57 subjects, which was investigated through a multidisciplinary 
approach unifying viral evolution and immunological patterns. 
 
The first studies aimed at characterizing HIV-1-specific CD8+ T cell responses and 
performing advanced evolutionary analysis in six HLA-B*5701 subjects with different 
risk of disease progression (Paper I and Paper II). Next, a new method to investigate 
differences in HIV-1 population dynamics through the analysis of the temporal 
structure of viral genealogy was developed (Paper III). Finally, this method was 
applied to investigate intra-host phylodynamic patterns and the emergence and 
population dynamics of archival viral strains in HLA-B*5701 and non-HLA-B*57 
subjects (Paper IV). The results will be presented and discussed in the following main 
sections: i) HIV-1 immune and viral factors in HLA-B*5701 low-risk and high-risk 
progressors; ii) Developing tools to analyze temporal structure of viral genealogies; iii) 
HIV-1 intra-host phylodynamic patterns and in-depth temporal structure analysis of 
viral genealogies in HLA-B*5701 subjects and non-HLA-B*57 controls. 
 
 
3.1 HIV-1 IMMUNE AND VIRAL FACTORS IN HLA-B*5701 LOW-RISK 
AND HIGH-RISK PROGRESSORS 
In Paper I, HIV-1 in vivo evolution and epitope-specific CD8+ T cell responses were 
investigated in six untreated HLA-B*5701 patients monitored from early infection for 
up to seven years. Three subjects were classified as high-risk progressors (HRPs) and 
three as low-risk progressors (LRPs) based on viral load and baseline CD4+ T cell 
counts (10-11 weeks post-infection, wpi) [67]. The focus was on the Gag p24-region 
since several HLA-B*5701-restricted epitopes (ISW9, KF11, TW10 and QW9) are 
located in this region of the viral genome. Immune responses were identified against 
wild-type and autologous variants of the epitopes. Interestingly, polyfunctional CD8+ T 
cell responses toward wild-type HLA-B*5701-restricted epitopes were found to be 
more robust in LRPs than HRPs. The fraction of CD8+ T cells coproducing IFN-$, 
MIP-1# and IL-2 in response towards the epitopes TW10 and QW9 were significantly 
higher in the LRP group (Figure 8). The LRPs also showed a significantly higher 
fraction of IL-2 producing CD8+ T cells (in response to wild-type epitopes) in early 
infection compared to HRPs. Importantly, a significant positive correlation between the 
fraction of IL-2-producing CD8+ T cells and the CD4+ T cell count was found when all 
subjects were included in the analysis. 
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Figure 8. Functional discrepancies 
of epitope-specific CD8+ T cell 
responses between HRPs and 
LRPs. Pie charts representing the 
fraction of CD8+ T cell responses 
towards each HLA-B*5701-
restricted wild-type epitope in 
Gag p24. One to four functions 
are illustrated by the colors 
yellow, orange, red and blue, 
respectively. Adapted from [136]. 
 
Parallel to the immunological findings, interesting evolutionary patterns were 
uncovered. In all study subjects, HIV-1 gag p24 sequences exhibited more substitutions 
in flanking regions than in HLA-B*5701-restricted epitopes, but sequence diversity and 
mean evolutionary rates were significantly lower in LRPs compared to HRPs (Paper 
I). Sequences also exhibited a higher degree of homoplasy in LRPs. More in-depth 
analyses revealed that this difference was mainly determined by significantly lower 
synonymous substitution rates (Paper II). The difference in synonymous substitution 
rates between the two groups of patients was especially significant for backbone 
branches, which represent the surviving viral population successfully emerging over 
time from sequential population bottlenecks (Figure 9, left). The viral quasispecies 
infecting LRPs were also characterized by a slower increase in synonymous divergence 
over time (Figure 9, right). 
 
  
Figure 9. Mean synonymous substitution rates (left) and synonymous divergence over the 
course of HIV-1 infection (right) for backbone branches in HLA-B*5701 subjects. HRPs (P1-
P3) and LRPs (P4-P6) are shown in orange and purple, respectively. Adapted from [136]. 
 
Additionally, p24 sequences exhibited more constrained mutational patterns along the 
major bottlenecks, as defined by the topological structure of the viral genealogy, of the 
quasispecies infecting LRPs (Paper I). Mutational events leading to changes in TW10 
and ISW9 (including upstream position 146) and the CypA-binding loop appeared to 
occur in a specific order (Figure 10, right). On the other hand, in HRPs, viral 
evolutionary patterns along population bottlenecks appeared to be less constrained and 
were characterized by the more frequent emergence of variants with amino acid 
replacements in the CypA-binding loop and/or other flanking regions (Figure 10, left). 
It is also important to mention that sequences in HRPs displayed the eventual 
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emergence of QW9 variants, while this epitope region was conserved in LRPs. The 
results indicate that HIV-1 evolution in HLA-B*5701 patients with a high baseline 
CD4+ T cell count was constrained by polyfunctional CD8+ T cell responses with a 
maintained ability to coproduce IL-2. This is strengthened by the significant correlation 
found between the fraction of IL-2-producing CD8+ T cells and CD4+ T cell count, 
which in turn could be associated with a lower synonymous substitution rate and risk of 
disease progression. There are also several studies that have underlined the important 
role of IL-2-producing CD8+ T cell functional subsets to mediate protective immunity 
at different stages of infection [137-139]. 
 
 
Figure 10. Maximum likelihood gag p24 genealogies (using only unique sequences) for HRP 
(left) and a LRP (right). Statistical support for specific branches are indicated by * (bootstrap > 
65% or aLRT p > 0.75) or ** (bootstrap > 65% and aLRT p > 0.75). Amino acid replacements 
along supported internal branches are indicated; the numbering refers to Gag amino acid 
position in HXB2, used as reference. Adapted from [136]. 
 
Several underlying mechanisms could potentially account for the observed differences 
in synonymous substitution rates and divergence over time between the two groups of 
patients. Since synonymous substitutions are neutral or nearly neutral [140], the HIV-1 
synonymous substitution rate is expected to be proportional to the viral replication rate 
[141]. The higher synonymous rates in HRPs could be the consequence of an infection 
with fitter viral variants characterized by faster replication, but in vitro replication 
capacity (RC) did not display any differences between the two groups of patients 
(Paper II). The pattern in synonymous substitution rates between HRPs and LRPs 
could not be explained by differences among subjects in CD4+ and CD8+ T cell 
activation or selection pressure either. However, there are some limitations in these 
studies that should be mentioned. First, the lack of significance for some analysis might 
be due to the small sample size and lack of statistical power (Paper I and Paper II). 
Second, no samples from the acute phase of HIV-1 infection (i.e. earlier than 11 wpi) 
were available to assess early events in terms of viral evolution and immune responses 
(Paper I) or to compare whether RC or T cell activation differed between the two 
groups of patients during primary infection (Paper II). Third, the RC assay only tested 
one part of the viral genome that may not fully capture the total viral replication 
capacity (Paper II). Nevertheless, the data suggest that neither T cell activation nor an 
initial infection with fitter viral variants would explain the difference in synonymous 
rates between HLA-B*5701 HRPs or LRPs. 
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In order to identify other potential mechanisms behind the observed differences in viral 
evolutionary rate, the correlation between mean nonsynonymous or synonymous rates 
for different branch sets (all, internal, backbone and external) and clinical parameters 
for each patient were analyzed (Paper II). It was found that higher baseline CD4+ T 
cell counts (10-11 wpi) were strongly correlated with lower HIV-1 mean synonymous 
substitution rates (R2 = 0.9, p = 0.002) along backbone branches (Figure 11). These 
results indicate lower replication rates and/or longer viral generation times in the LRPs 
compared to HRPs. They also suggest that HLA-B*5701 subjects with higher baseline 
CD4+ T cell counts (> 750 cells/mm3 at 10-11 wpi) are capable of keeping HIV-1 
replication under better control during the course of the infection. Such an observation 
is in agreement with results presented in Paper I showing more constrained viral 
evolution in LRPs, probably linked to a more robust HLA-B*5701-specific CD8+ T cell 
response. There is, indeed, evidence that the emergence of escape mutations in p24, as 
a consequence of CD8+ T cell responses, can negatively affect viral fitness [142], and 
thereby be indirectly responsible for control of viral replication, longer generation 
times, and lower risk to progress to AIDS. 
 
 
Figure 11. Mean synonymous rates for backbone branches vs. CD4+ T cell count at baseline for 
each subject. Strong inverse correlation between mean synonymous rates and baseline CD4+ T 
cell counts (10-11 wpi) by pooling together estimates for all HLA-B*5701 subjects. The 
correlation is highly significant (p = 0.002). 
 
The overall findings may indicate that polyfunctional CD8+ T cell responses, directed 
towards HLA-B*5701-restricted epitopes, with specific functional profiles are the 
underlying mechanism of the observed difference in viral evolutionary rates between 
HLA-B*5701 subjects with different baseline CD4+ T cell counts. However, 
constrained HIV-1 evolution could also be the direct or indirect result of other host 
factors, which subsequently affect CD8+ T cell polyfunctionality. It is also important to 
consider that the focus and study design of the present work cannot exclude the role of 
individual responses restricted by alleles other than HLA-B*5701.  
 
In summary, the first two papers showed that subjects with high baseline CD4+ T cell 
counts (LRPs) displayed viral quasispecies evolving along more constrained mutational 
patterns, characterized by lower synonymous substitution rates, less changes in flanking 
regions, and no emergence of QW9 variants. The findings in Paper I and Paper II also 
revealed that these subjects had specific HLA-linked immune responses, lower 
replication rate and lower risk of HIV-1 disease progression. The integration of 
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experimental data with coalescent-based estimates allowed the development of, for the 
first time, a possible explanation for the correlation between HIV-1 in vivo replication 
rate and different risk of disease progression in HLA-B*5701 subjects. 
 
 
3.2 DEVELOPING TOOLS TO ANALYZE TEMPORAL STRUCTURE OF 
VIRAL GENEALOGIES 
To further assess the findings of Paper I and Paper II and evaluate them in the context 
of HIV-1 intra-host population dynamics, a novel methodology was adopted to 
investigate the temporal structure of phylogenetic trees inferred from longitudinal 
samples. 
 
In Paper III, a new topological measure, called temporal clustering (TC), which 
characterizes the temporal structure of a serial samples phylogeny, was implemented in 
the R language. A set of R scripts, called PhyloTempo, integrated TC calculations and 
several other tree topological measures in a user-friendly interface. The comparison of 
the TC statistic with other measures provides multifaceted insights on the evolutionary 
and population dynamic processes shaping serially sampled genealogies of pathogenic 
viruses. 
 
The features and applicability of PhyloTempo were tested on longitudinal intra-host 
human and simian immunodeficiency virus population data sets. The intra-host HIV-1 
data set consisted of gag p24 sequences from the HLA-B*5701 subjects described in 
Paper I and Paper II. PhyloTempo estimates the TC statistic and implements a 
graphical output interface displaying phylogenetic trees with maximum likelihood 
reconstructed ancestral states (Paper III). TC analysis can reveal important 
information of archival viral strains and the impact of continuous immune selection on 
viral population dynamics.  
 
By running the HLA-B*5701 data sets, several biological insights emerged. First, TC 
did not correlate with any previously described topological tree measure, implying that 
the new TC statistics evaluates aspects of the evolutionary process not captured by 
existing methods. Second, despite several studies having interpreted temporally 
structured phylogenies as evidence of sequential viral population bottlenecks driven by 
continuous selection pressure [73, 88, 90, 143], TC did not correlate with estimate 
dN/dS ratios in the different data sets analysed. Additionally, archival viral strains 
expressed in cellular reservoirs would decrease the temporal structure of serially 
sampled genealogies, because sequences from later time points may share a most recent 
common ancestor with sequences collected much earlier in infection [144]. 
 
 
3.3 HIV-1 INTRA-HOST PHYLODYNAMIC PATTERNS AND IN-DEPTH 
TEMPORAL STRUCTURE ANALYSIS OF VIRAL GENEALOGIES IN 
HLA-B*5701 SUBJECTS AND NON-HLA-B*57 CONTROLS 
To obtain insights into how host genetic factors may impact HIV-1 population 
dynamics and disease progression, a control group of non-HLA-B*57 subjects was also 
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included in the study cohort. In Paper IV, temporal structure of HIV-1 intra-host 
genealogies, as well as viral phylodynamic patterns, were investigated in the six HLA-
B*5701 subjects and six additional non-HLA-B*57 controls to compare HIV-1 
population dynamics in subjects with different genetic backgrounds. The HIV-1 intra-
host demographic history was inferred for each subject. A peak in viral effective 
population size (Ne), representing the number of effectively infectious viral genomes 
(i.e. the ones effectively contributing to the next generation), was observed within the 
first year of infection in control subjects. This peak in Ne was also often followed by a 
second increase later in infection. In the HLA-B*5701 subjects, on the other hand, 
either constant Ne or Ne increase two to four years post-infection was observed (Figure 
12). 
 
  
!"#$%&'()*%+,*-%"./$0-",.1%
%
Figure 12. HIV-1 demographic history in a HLA-B*5701 subject (left) and a non-HLA-B*57 
control (right). Bayesian skyline plots (BSPs) representing non-parametric estimates of the viral 
effective population time (Ne) over time. The thick line represents median Ne estimates, while 
the thin lines indicate the upper and lower 95% high posterior density (HPD) for the estimate of 
Ne. The estimate of Ne is on the y-axis and time is on the x-axis. 
 
In-depth TC analysis revealed earlier emergence of archival viral strains in non-HLA-
B*57 (1.8 – 2.5 years post infection) than in HLA-B*5701 subjects (2.7 – 5.5 years 
post-infection (Figure 13). The TC analysis also showed that re-emergence of archival 
viral strains appeared over a significantly shorter time (p = 0.015) in non-HLA-B*57 
controls (1 year) compared to HLA-B*5701 subjects (2 years) (Figure 14). 
 
The earlier Ne peak observed in non-HLA-B*57 control subjects was likely influenced 
by multiple factors, including earlier and regular detection of archival viral strains in 
the plasma. The emergence or re-emergence of archival strains seemed to contribute 
less often to the HIV-1 population diversity infecting subjects that carry the HLA-
B*5701 protective allele. It is possible that in non-HLA-B*57 control subjects, 
potential reservoirs may be re-activated earlier and/or more often than in subjects 
carrying the protective allele, which would result in the replication of the archival 
viruses detected in the longitudinal plasma samples. 
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Figure 13. Temporal Clustering analysis in twelve patients: six HLA-B*5701 subjects (P1-
P6) and six non-HLA-B*57 control subjects (P7-P12). Each bar indicates the earliest 
sampling time (Ti) of an inferred time transition (from Ti to Tj with i<j) that was significantly 
more frequent (p<0.05) than expected by chance across the HIV-1 genealogy from each 
subject (x-axis). This is the first sampling time at which an archival viral sequence could be 
detected in the genealogy. Time (y-axis) is given in days post-infection. 
 
 
 
 
Figure 14. Length of inferred ancestral time transitions across genealogy samples. Squares 
indicate inferred ancestral time transitions (from Ti to Tj with i<j) that were significantly 
more frequent (p<0.05) than expected by chance across the HIV-1 genealogy from each 
subject (x-axis). The y-axis indicates the time interval (!T= Tj-Ti with i<j) for each transition 
and represents the waiting time for the re-emergence of archival strains. 
 
The different dynamics in HLA-B*5701 and non-HLA-B*57 subjects is possibly the 
result of the different genetic backgrounds and the interplay between immune system 
and viral quasispecies. Therefore, the study in Paper IV provided novel insights into 
how host genetic factors may impact viral population dynamics and HIV-1 disease 
progression. 
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4 CONCLUSIONS AND FUTURE PERSPECTIVE 
The exact mechanisms underlying HIV-1 pathogenesis and varying disease outcome 
still remain elusive after 30 years of research. Correlates of protection remain 
undefined, but investigating HIV-1 disease progression may reveal essential knowledge 
for successful vaccine design, and potentially lead to the development of therapies able 
to eradicate the infection. However, it may require a multidisciplinary approach 
combining both fields of HIV virology and immunology to obtain a better picture of the 
complex interplay between HIV-1 intra-host evolution and immune system. This thesis 
summarizes several studies where viral evolution and immunological patterns were 
unified to investigate risk of HIV-1 disease progression in HLA-B*5701 subjects. A 
method was also implemented to investigate the temporal structure and phylodynamic 
patterns of HIV-1 intra-host genealogies from subjects with different genetic 
backgrounds. The thesis’ work resulted in several main findings: 
 
• HLA-B*5701 subjects with higher baseline CD4+ T cell counts had 
significantly lower HIV-1 intra-host gag p24 sequence diversity, lower 
evolutionary rate and more constrained mutational pattern compared to 
subjects with lower baseline CD4+ T cell counts (Paper I). 
• The fraction of polyfunctional and IL-2-producing CD8+ T cell responses, 
particularly to TW10 and QW9 epitopes, were more robust in HLA-B*5701 
subjects with higher baseline CD4+ T cell counts (Paper I). 
• A significant correlation was found between the fraction of IL-2-producing 
CD8+ T cells and CD4+ T cell count for the HLA-B*5701 subjects (Paper I). 
• HLA-B*5701 subjects with higher baseline CD4+ T cell counts had 
significantly lower HIV-1 synonymous substitution rates compared to subjects 
with lower baseline CD4+ T cell counts (Paper II). 
• A significant inverse correlation between baseline CD4+ T cell counts and 
mean HIV-1 synonymous substitution rates was found for the HLA-B*5701 
subjects (Paper II). 
• PhyloTempo, a new program implemented to analyze temporal structure of 
viral genealogies, revealed that the TC statistic did not correlate with any 
previously described topological tree measure and may evaluate aspects of the 
evolutionary process not captured by existing methods (Paper III). 
• Changes in viral effective population size (Ne) over time were more 
constrained in HLA-B*5701 subjects compared to non-HLA-B*57 controls 
(Paper IV). 
• HLA-B*5701 subjects displayed later and less regular re-emergence of 
archival sequences compared to non-HLA-B*57 controls (Paper IV). 
 
Most studies so far have focused either on intra-host viral evolution or on functional 
aspects of the immune system. Few attempts have been made to apply the full 
phylodynamic framework specifically developed to investigate the interplay between 
pathogen evolution and host immune response [88]. Immunological (REFs) and 
evolutionary studies [90, 132, 145] have provided important insights in the HIV field, 
but correlates of protection still remain elusive because, as demonstrated in the 
present work, they require study design and experimental settings able to integrate 
both immunological and viral evolutionary findings. 
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Paper I provided insights into the roles of polyfunctional CD8+ T cells and IL-2-
producing T cells in constraining the tempo and mode of HIV-1 evolution in HLA-
B*5701 subjects. This suggests that these biomarkers may serve as additional measures 
of risk for disease progression, including both viral evolutionary dynamics and host 
immune responses [92]. Additionally, Paper II provided a possible mechanism for 
different risk of HIV-1 disease progression in HLA-B*5701 subjects. This may have 
significant translational impact on clinical practice since synonymous rates, which are 
proportional to in vivo replication rates, could be used as an evolutionary marker of 
disease progression in HLA-B*5701 subjects. Finally, Paper IV provided insights into 
how host genetic factors impact viral population dynamics and HIV-1 disease 
progression.  
 
Correlates of protection, in other words, likely involve both evolutionary and 
immunological biomarkers. Through a study design including extensive clinical and 
immunological observations (measurement of polyfunctional CD8+ T cell responses, 
T cell activation, HLA-typing, CD4+ T cell counts, viral load), as well as high-
resolution phylodynamic analysis (genealogies from longitudinal samples, Bayesian 
estimates of evolutionary rates and effective population size, and temporal structure 
analysis of viral genealogies) it is possible to unify viral and immunological patterns 
within a coherent model. By using this approach, new models could be developed to 
explain HIV-1 pathogenesis and risk of disease progression, as well as shed new light 
on how host genetic factors impact HIV-1 intra-host population dynamics. 
 
The studies described in this thesis have provided valuable insights in the HIV field, 
but also call for further investigation, as several key questions remain unanswered. 
First, in order to confirm the findings in Papers I-IV and increase statistical power, the 
same type of studies would need to be performed on a larger number of patients. 
Second, samples from acute infection should be included, if possible, to characterize 
the earliest immunological and evolutionary events. Third, it is important to further 
investigate the viral dynamics in the non-HLA-B*57 control subjects by obtaining non-
synonymous and synonymous divergence, replication capacity and T cell activation 
data. Then, the same methods and analysis described in Paper II for the HLA-B*5701 
subjects could be applied to the control data to obtain these results. It is also important 
to stress that all the studies included in this thesis are based on the gag p24-region. 
Therefore, knowledge of immunological and viral factors in other regions of the HIV-1 
genome would be of value and the data could be obtained by applying the 
methodologies described in Paper I. It is already known, for example, that several 
HLA-B*5701-restricted epitopes are located in nef [146] and it would be interesting to 
investigate if any differences in this genomic region could be found in the HLA-
B*5701 subjects with different risk of disease progression. 
 
Finally, this thesis shows the power of using a multidisciplinary approach that may 
have potential translational impact not only in the HIV field, but also in the study of 
other fast-evolving viruses by providing a general framework unifying viral evolution 
and immunological patterns. 
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